Table 1.

Baseline demographics and disease characteristics

Dosing schedule	7 on/7 off in a 28-day cycle							7 on/14 off in a 21-day cycle		Total
MK-8242 dose	30 mg QD	60 mg QD	120 mg QD	250 mg QD	120 mg BID	170 mg BID	250 mg BID	210 mg BID	300 mg BID
Number enrolled	1	1	3	1	4	3	3	6	4	26
Sex (male), no. (%)	1 (100)	1 (100)	2 (66.7)	1 (100)	4 (100)	2 (66.7)	3 (100)	3 (50)	3 (75)	20 (76.9)
Age (years), mean ± SD	63.0	74.0	72.3 ± 6.7	77.0	58.8 ± 18.5	63.3 ± 14.6	72.3 ± 12.5	63.5 ± 11.5	41.0 ± 14.3	62.2 ± 15.5
Race, no. (%)
White	1 (100)	1 (100)	3 (100)	1 (100)	4 (100)	3 (100)	3 (100)	5 (83.3)	3 (75)	24 (92.3)
Other	0	0	0	0	0	0	0	1 (16.7)	1 (25)	2 (7.6)
Primary Diagnosis
Recurrent AML	0	0	2 (66.7)	1 (100)	0	0	2 (66.7)	3 (50)	2 (50)	10 (38.5)
Refractory AML	1 (100)	1 (100)	1 (33.3)	0	4 (100)	3 (100)	1 (33)	3 (50)	2 (50)	16 (61.5)
WT p53 positive	0	0	1 (33.3)	0	0	1 (33.3)	0	3 (50.0)	2 (50.0)	7 (26.9)
WT p53 negative	1 (100)	1 (100)	2 (66.7)	1 (100)	4 (100)	2 (66.7)	1 (33.3)	3 (50.0)	1 (25.0)	16 (61.5)
Genetic testing not performed	0	0	0	0	0	0	2 (66.7)	0	1 (25.0)	3 (11.5)